Pre-made Suptavumab benchmark antibody ( Whole mAb, anti-RSV gpF therapeutic antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Suptavumab biosimilar, Whole Mab: Anti-RSV gpF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Suptavumab (INN; development code (REGN2222) is a humanized monoclonal antibody designed for the prevention of medically attended lower respiratory tract disease due to respiratory syncytial virus.
| Products Name (INN Index) | Pre-Made Suptavumab biosimilar, Whole Mab: Anti-RSV gpF therapeutic antibody |
|---|---|
| INN Name | Suptavumab |
| Target | RSV gpF |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Regeneron Pharmaceuticals |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Respiratory syncytial virus infections |
| Development Tech | VelocImmune Mouse;VelociGene |
| Previous Name | NA |
| Gm Offical Target Name | RSV gpF |
| Package |
